Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051838 | 0.94 | CASP2 (0.61) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL97364 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL7554107 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL4683998 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL97611 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL7556481 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL7555060 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL9432343 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL9195404 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL7557934 | 0.92 | CASP2 (0.71) | FAAHCASP2DNM1NAAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| EP-2464623-A1 | THE RING OPENING OF LACTONES AND LACTAMS | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8058307-B2 | Alcanoic acid amides substituted by saturated O-heterocycles | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-0514667-B1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5244898-A | Vasopressin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | LSS, APH1A, OTUB1 | FAAH 2381/4885CASP2 1069/4885DNM1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.